{"id":72875,"date":"2026-04-16T18:44:34","date_gmt":"2026-04-16T13:14:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=72875"},"modified":"2026-04-16T18:44:35","modified_gmt":"2026-04-16T13:14:35","slug":"morepen-laboratories-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/","title":{"rendered":"Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>Morepen Laboratories (NSE: MOREPAN) is scheduled to declare its Q4 FY26 (January\u2013March 2026) results on May 12, 2026. The stock trades at Rs 48 as of April 2026 \u2014 down -41% from its 52-week high of Rs 82 \u2014 entering the most consequential quarterly results event of FY26. Q4 FY26 delivers the complete annual FY26 performance and the first formal FY27 management guidance.<\/p><p>This Q4 FY26 results preview covers the confirmed date, analyst consensus estimates, five key performance factors, five risks, analyst ratings, and the complete share price outlook for Morepen Laboratories.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get free investment predictions from SEBI-registered analysts on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Morepen_Laboratories_Q4_Results_2026_Date\" title=\"Morepen Laboratories Q4 Results 2026 Date\">Morepen Laboratories Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Why_Q4_FY26_Matters\" title=\"Why Q4 FY26 Matters\">Why Q4 FY26 Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Morepen_Laboratories_Q4_FY26_Earnings_Estimates\" title=\"Morepen Laboratories Q4 FY26 Earnings Estimates\">Morepen Laboratories Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#5_Key_Factors_Driving_Morepen_Laboratories_Q4_FY26_Performance\" title=\"5 Key Factors Driving Morepen Laboratories Q4 FY26 Performance\">5 Key Factors Driving Morepen Laboratories Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#1_India_Branded_Generic_Growth\" title=\"1. India Branded Generic Growth\">1. India Branded Generic Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#2_Generic_Oncology_Pipeline\" title=\"2. Generic Oncology Pipeline\">2. Generic Oncology Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#3_US_API_Export_Recovery\" title=\"3. US API Export Recovery\">3. US API Export Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#4_New_Product_Launches\" title=\"4. New Product Launches\">4. New Product Launches<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#5_Field_Force_Productivity\" title=\"5. Field Force Productivity\">5. Field Force Productivity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#5_Risks_to_Watch_in_Morepen_Laboratories_Q4_FY26\" title=\"5 Risks to Watch in Morepen Laboratories Q4 FY26\">5 Risks to Watch in Morepen Laboratories Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Risk_1_Input_Cost_Volatility\" title=\"Risk 1: Input Cost Volatility\">Risk 1: Input Cost Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Risk_2_Revenue_Concentration_Risk\" title=\"Risk 2: Revenue Concentration Risk\">Risk 2: Revenue Concentration Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Risk_3_Competitive_Pressure\" title=\"Risk 3: Competitive Pressure\">Risk 3: Competitive Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Risk_4_Regulatory_Environment\" title=\"Risk 4: Regulatory Environment\">Risk 4: Regulatory Environment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Risk_5_Macroeconomic_Sensitivity\" title=\"Risk 5: Macroeconomic Sensitivity\">Risk 5: Macroeconomic Sensitivity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Morepen_Laboratories_Share_Price_and_Analyst_Ratings\" title=\"Morepen Laboratories Share Price and Analyst Ratings\">Morepen Laboratories Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_When_is_Morepen_Laboratories_Q4_results_2026_date\" title=\"Q: When is Morepen Laboratories Q4 results 2026 date?\">Q: When is Morepen Laboratories Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_What_is_Morepen_Laboratories_Q4_FY26_revenue_estimate\" title=\"Q: What is Morepen Laboratories Q4 FY26 revenue estimate?\">Q: What is Morepen Laboratories Q4 FY26 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_What_is_Morepen_Laboratories_share_price_ahead_of_Q4_results\" title=\"Q: What is Morepen Laboratories share price ahead of Q4 results?\">Q: What is Morepen Laboratories share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_Will_Morepen_Laboratories_declare_a_dividend_in_Q4_FY26\" title=\"Q: Will Morepen Laboratories declare a dividend in Q4 FY26?\">Q: Will Morepen Laboratories declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_What_is_Morepen_Laboratories_Q4_FY26_PAT_estimate\" title=\"Q: What is Morepen Laboratories Q4 FY26 PAT estimate?\">Q: What is Morepen Laboratories Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_What_were_Morepen_Laboratories_Q3_FY26_results\" title=\"Q: What were Morepen Laboratories Q3 FY26 results?\">Q: What were Morepen Laboratories Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\" title=\"Q: When do TCS and Infosys announce Q4 results 2026?\">Q: When do TCS and Infosys announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Q_Is_Morepen_Laboratories_a_good_investment_ahead_of_Q4_results\" title=\"Q: Is Morepen Laboratories a good investment ahead of Q4 results?\">Q: Is Morepen Laboratories a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Morepen_Laboratories_Q4_Results_2026_Date\"><\/span><strong>Morepen Laboratories Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Morepen Laboratories Q4 FY26 results date is May 12, 2026. The board of directors will approve the audited Q4 and full-year FY26 financial results, consider a final dividend for FY26, and provide management&#8217;s first commentary on the FY27 business outlook.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 Results Date<\/strong><\/td><td><strong>Key Metric to Watch<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026 (Declared)<\/td><td>FY27 CC guidance + deal TCV<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td>CC revenue growth range<\/td><\/tr><tr><td>HCL Technologies<\/td><td>April 22, 2026<\/td><td>EBIT margin + services growth<\/td><\/tr><tr><td>Narayana Hrudayalaya<\/td><td>May 10, 2026<\/td><td>ARPOB + occupancy rate<\/td><\/tr><tr><td>Morepen Laboratories<\/td><td>May 12, 2026<\/td><td>See estimates below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Q4_FY26_Matters\"><\/span><strong>Why Q4 FY26 Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of FY2025\u201326 and delivers the full-year annual results alongside the first FY27 business outlook from management. For Morepen Laboratories in the Pharma \/ API \/ OTC Consumer sector, Q4 captures peak-season demand dynamics that typically determine whether the full-year performance meets, beats, or misses analyst expectations.<\/p><p>The Morepen Laboratories board&#8217;s dividend recommendation on May 12, 2026 will also be closely watched as it signals confidence in FY26 cash flow quality and FY27 business trajectory.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Morepen_Laboratories_Q4_FY26_Earnings_Estimates\"><\/span><strong>Morepen Laboratories Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16184110\/Morepen-Laboratories-Q4-FY26-analyst-estimates-%E2%80%94-Revenue-Rs-520-Cr-PAT-Rs-22-Cr-1024x536.jpg\" alt=\"Morepen Laboratories Q4 FY26 analyst estimates \u2014 Revenue Rs 520 Cr, PAT Rs 22 Cr \" class=\"wp-image-72882\"\/><\/figure><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium analyst research on Univest<\/strong><\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Trend<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 520 Cr<\/td><td>Rs 473 Cr<\/td><td>Sequential improvement expected<\/td><\/tr><tr><td>Net Profit (PAT)<\/td><td>Rs 22 Cr<\/td><td>Rs 19 Cr<\/td><td>Normalisation in progress<\/td><\/tr><tr><td>Operating Margin<\/td><td>EBITDA 10%<\/td><td>Q3 FY26 level<\/td><td>Stable to improving<\/td><\/tr><tr><td>Volume \/ Revenue Growth<\/td><td>+10% volume YoY<\/td><td>Prior quarter<\/td><td>YoY improvement expected<\/td><\/tr><tr><td>Final Dividend (Expected)<\/td><td>Rs 0.50<\/td><td>FY26 interim dividends<\/td><td>Board decision on May 12, 2026<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <strong>Morepen Laboratories<\/strong> live on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a> \u2014 real-time fundamentals, FII\/DII flows, and analyst ratings.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for live Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_Driving_Morepen_Laboratories_Q4_FY26_Performance\"><\/span><strong>5 Key Factors Driving Morepen Laboratories Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_India_Branded_Generic_Growth\"><\/span><strong>1. India Branded Generic Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>India pharmaceutical market growing at 8-10% annually. Q4 captures year-end prescription momentum and seasonal anti-infective demand.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Generic_Oncology_Pipeline\"><\/span><strong>2. Generic Oncology Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>First-to-file generic cancer drugs (paclitaxel, docetaxel, imatinib) command 180-day exclusivity in regulated markets \u2014 highest margin window in pharma.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_US_API_Export_Recovery\"><\/span><strong>3. US API Export Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>API (Active Pharmaceutical Ingredient) export to US and European formulation companies provides volume growth beyond domestic market.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_New_Product_Launches\"><\/span><strong>4. New Product Launches<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>CDSCO approvals for new OTC and prescription drugs expand domestic addressable market.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Field_Force_Productivity\"><\/span><strong>5. Field Force Productivity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Medical representative coverage quality determines prescription generation pace. Year-end prescription activity in Q4 is seasonally strong.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Morepen_Laboratories_Q4_FY26\"><\/span><strong>5 Risks to Watch in Morepen Laboratories Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_Input_Cost_Volatility\"><\/span><strong>Risk 1: Input Cost Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Raw material and input cost changes can compress margins unexpectedly within a quarter.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Revenue_Concentration_Risk\"><\/span><strong>Risk 2: Revenue Concentration Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Customer or geographic concentration creates quarterly revenue variance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_3_Competitive_Pressure\"><\/span><strong>Risk 3: Competitive Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Intensified sector competition may require price or volume concessions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_4_Regulatory_Environment\"><\/span><strong>Risk 4: Regulatory Environment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Policy and regulatory changes can create compliance cost or revenue risks.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_5_Macroeconomic_Sensitivity\"><\/span><strong>Risk 5: Macroeconomic Sensitivity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Global and domestic conditions \u2014 tariffs, interest rates, consumption \u2014 affect demand.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Morepen_Laboratories_Share_Price_and_Analyst_Ratings\"><\/span><strong>Morepen Laboratories Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004.jpeg\" alt=\"Morepen Laboratories share price and analyst ratings \u2014 Q4 FY26 preview\" class=\"wp-image-72878\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 48<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 82<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 38<\/td><\/tr><tr><td>1-Year Return<\/td><td>-41%<\/td><\/tr><tr><td>Market Capitalisation<\/td><td>Rs 1,800 Cr<\/td><\/tr><tr><td>Sector<\/td><td>Pharma \/ API \/ OTC Consumer<\/td><\/tr><tr><td>NSE Ticker<\/td><td>MOREPAN<\/td><\/tr><tr><td>Q4 Results Date<\/td><td>May 12, 2026<\/td><\/tr><\/tbody><\/table><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Thesis Summary<\/strong><\/td><\/tr><tr><td>Motilal Oswal<\/td><td>BUY<\/td><td>Q4 recovery potential; sector tailwinds intact<\/td><\/tr><tr><td>YES Securities<\/td><td>ADD<\/td><td>Earnings inflection expected; FY27 guidance key<\/td><\/tr><tr><td>Kotak Institutional<\/td><td>NEUTRAL<\/td><td>Fair valued at current levels; execution key<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Morepen Laboratories Q4 FY26 results on May 12, 2026 will be the most important quarterly event of FY26. At Rs 48 \u2014 down -41% from its 52-week high of Rs 82 \u2014 the stock has already priced in significant headwinds. Revenue above Rs 520 Cr with EBITDA 10% would constitute a beat against current analyst consensus. Management&#8217;s FY27 guidance is the primary re-rating catalyst.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making investment decisions.<\/p><p>For more Q4 FY26 results previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_is_Morepen_Laboratories_Q4_results_2026_date\"><\/span><strong>Q: When is Morepen Laboratories Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Morepen Laboratories Q4 FY26 results date is May 12, 2026. The board will approve the audited Q4 and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Morepen_Laboratories_Q4_FY26_revenue_estimate\"><\/span><strong>Q: What is Morepen Laboratories Q4 FY26 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus Q4 FY26 revenue estimate for Morepen Laboratories is Rs 520 Cr. Q3 FY26 actual revenue was Rs 473 Cr. Actual results may differ based on operating conditions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Morepen_Laboratories_share_price_ahead_of_Q4_results\"><\/span><strong>Q: What is Morepen Laboratories share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Morepen Laboratories trades at Rs 48 as of April 2026. 52-week high is Rs 82 and 52-week low is Rs 38. The 1-year return is -41%. Market cap is Rs 1,800 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Will_Morepen_Laboratories_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Q: Will Morepen Laboratories declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Morepen Laboratories is expected to declare a final dividend of Rs 0.50 for FY26, subject to board approval on May 12, 2026 and AGM shareholder ratification. Verify the actual announcement before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Morepen_Laboratories_Q4_FY26_PAT_estimate\"><\/span><strong>Q: What is Morepen Laboratories Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus Q4 FY26 PAT estimate for Morepen Laboratories is Rs 22 Cr. Q3 FY26 actual PAT was Rs 19 Cr. These are analyst estimates and subject to quarterly variance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_were_Morepen_Laboratories_Q3_FY26_results\"><\/span><strong>Q: What were Morepen Laboratories Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Morepen Laboratories reported Q3 FY26 revenue of Rs 473 Cr and PAT of Rs 19 Cr. The Q4 FY26 results on May 12, 2026 provide the full-year FY26 comparison and first FY27 guidance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\"><\/span><strong>Q: When do TCS and Infosys announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. HCL Technologies declared on April 22. See the earnings calendar table above for other result dates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Is_Morepen_Laboratories_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Q: Is Morepen Laboratories a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This article does not constitute investment advice. Morepen Laboratories at Rs 48 is -41% below its 52-week peak of Rs 82. Review the five growth factors and five risks above. Consult a SEBI-registered financial advisor before making any investment decision.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/chembond-chemicals-q4-results-2026\">Chembond Chemicals Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/chambal-fertilizers-and-chemicals-q4-results-2026\">Chambal Fertilizers &amp; Chemicals Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/chaman-lal-setia-exports-q4-results-2026\">Chaman Lal Setia Exports Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/chalet-hotels-q4-results-2026\">Chalet Hotels Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cerebra-integrated-technologies-q4-results-2026\">Cerebra Integrated Technologies Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Morepen Laboratories (NSE: MOREPAN) is scheduled to declare its Q4 FY26 (January\u2013March 2026) results on May 12, 2026. The stock trades at Rs 48 as of April 2026 \u2014 down -41% from its 52-week high of Rs 82 \u2014 entering the most consequential quarterly results event of FY26. Q4 FY26 delivers the complete annual FY26<\/p>\n","protected":false},"author":28,"featured_media":72891,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-72875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1776345321:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1004.jpeg\";a:2:{s:2:\"id\";i:72878;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16183919\/image-1004.jpeg\";a:2:{s:2:\"id\";i:72878;s:11:\"source_type\";s:13:\"media-library\";}s:133:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Morepen-Laboratories-Q4-FY26-analyst-estimates-\u2014-Revenue-Rs-520-Cr-PAT-Rs-22-Cr.jpg\";a:2:{s:2:\"id\";i:72882;s:11:\"source_type\";s:13:\"media-library\";}s:142:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Morepen-Laboratories-Q4-FY26-analyst-estimates-\u2014-Revenue-Rs-520-Cr-PAT-Rs-22-Cr-1024x536.jpg\";a:2:{s:2:\"id\";i:72882;s:11:\"source_type\";s:13:\"media-library\";}s:165:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16184110\/Morepen-Laboratories-Q4-FY26-analyst-estimates-\u2014-Revenue-Rs-520-Cr-PAT-Rs-22-Cr.jpg\";a:2:{s:2:\"id\";i:72882;s:11:\"source_type\";s:13:\"media-library\";}s:174:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16184110\/Morepen-Laboratories-Q4-FY26-analyst-estimates-\u2014-Revenue-Rs-520-Cr-PAT-Rs-22-Cr-1024x536.jpg\";a:2:{s:2:\"id\";i:72882;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_seo_score":["80"],"rank_math_primary_category":["842"],"rank_math_description":["Morepen Laboratories Q4 results date is May 12, 2026. Revenue estimate Rs 520 Cr, PAT estimate Rs 22 Cr. Key factors, risks, analyst ratings and share price outlook for 2026."],"rank_math_title":["Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_focus_keyword":["Morepen Laboratories Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["72891"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8330"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/16184336\/Morepen-Laboratories-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/72875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=72875"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/72875\/revisions"}],"predecessor-version":[{"id":72898,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/72875\/revisions\/72898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/72891"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=72875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=72875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=72875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}